This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maesaki, S.
Right arrow Articles by Kohno, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maesaki, S.
Right arrow Articles by Kohno, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2000, p. 1728-1730, Vol. 44, No. 6
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Efficacy of FK463, a (1,3)-beta -D-Glucan Synthase Inhibitor, in Disseminated Azole-Resistant Candida albicans Infection in Mice

Shigefumi Maesaki, Mohammad Ashraf Hossain, Yoshitsugu Miyazaki, Kazunori Tomono, Takayoshi Tashiro, and Shigeru Kohno*

The Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki 852-8501, Japan

Received 28 September 1999/Returned for modification 16 January 2000/Accepted 17 February 2000

The efficacy of FK463, a new (1,3)-beta -D-glucan synthase inhibitor, against azole-resistant Candida albicans strains has been studied. The MIC of FK463 was lower than those of azoles and amphotericin B against CDR1-expressing C26 and CaMDR-expressing C40 strains. All mice treated with FK463 (1 mg/kg) survived disseminated murine candidiasis. The fungal burden in the kidney after 6 days was markedly reduced after therapy with FK463 and amphotericin B sodium deoxycholate, and plasma (1,3)-beta -D-glucan concentration was found to be lower in FK463-treated mice. In our study, FK463 was found to be a potent antifungal agent against disseminated infection with azole-resistant C. albicans.

* Corresponding author. Mailing address: Second Department of Internal Medicine, Nagasaki University School of Medicine, Sakamoto 1-7-1, Nagasaki 852-8501, Japan. Phone: 81 95 849 7271. Fax: 81 95 849 7285. E-mail: s-kohno{at}net.nagasaki-u.ac.jp.

Antimicrobial Agents and Chemotherapy, June 2000, p. 1728-1730, Vol. 44, No. 6
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Keirns, J., Sawamoto, T., Holum, M., Buell, D., Wisemandle, W., Alak, A. (2007). Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults. Antimicrob. Agents Chemother. 51: 787-790 [Abstract] [Full Text]  
  • Messer, S. A., Diekema, D. J., Boyken, L., Tendolkar, S., Hollis, R. J., Pfaller, M. A. (2006). Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp.. J. Clin. Microbiol. 44: 324-326 [Abstract] [Full Text]  
  • Ninomiya, M., Mikamo, H., Tanaka, K., Watanabe, K., Tamaya, T. (2005). Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice. J Antimicrob Chemother 55: 587-590 [Abstract] [Full Text]  
  • Carver, P. L (2004). Micafungin. The Annals of Pharmacotherapy 38: 1707-1721 [Abstract] [Full Text]  
  • Arikan, S., Yurdakul, P., Hascelik, G. (2003). Comparison of Two Methods and Three End Points in Determination of In Vitro Activity of Micafungin against Aspergillus spp.. Antimicrob. Agents Chemother. 47: 2640-2643 [Abstract] [Full Text]  
  • Andes, D., Marchillo, K., Lowther, J., Bryskier, A., Stamstad, T., Conklin, R. (2003). In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase Inhibitor, in a Murine Candidiasis Model. Antimicrob. Agents Chemother. 47: 1187-1192 [Abstract] [Full Text]  
  • Nakai, T., Uno, J., Ikeda, F., Tawara, S., Nishimura, K., Miyaji, M. (2003). In Vitro Antifungal Activity of Micafungin (FK463) against Dimorphic Fungi: Comparison of Yeast-Like and Mycelial Forms. Antimicrob. Agents Chemother. 47: 1376-1381 [Abstract] [Full Text]  
  • Luque, J. C., Clemons, K. V., Stevens, D. A. (2003). Efficacy of Micafungin Alone or in Combination against Systemic Murine Aspergillosis. Antimicrob. Agents Chemother. 47: 1452-1455 [Abstract] [Full Text]  
  • Denning, D. W. (2002). Echinocandins: a new class of antifungal. J Antimicrob Chemother 49: 889-891 [Full Text]  
  • Petraitis, V., Petraitiene, R., Groll, A. H., Roussillon, K., Hemmings, M., Lyman, C. A., Sein, T., Bacher, J., Bekersky, I., Walsh, T. J. (2002). Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother. 46: 1857-1869 [Abstract] [Full Text]  
  • Groll, A. H., Mickiene, D., Petraitis, V., Petraitiene, R., Ibrahim, K. H., Piscitelli, S. C., Bekersky, I., Walsh, T. J. (2001). Compartmental Pharmacokinetics and Tissue Distribution of the Antifungal Echinocandin Lipopeptide Micafungin (FK463) in Rabbits. Antimicrob. Agents Chemother. 45: 3322-3327 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»